NCT00517439 - A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. | Biotech Hunter

Enrollment

516

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Copegus

1000/1200mg po daily for 24 weeks

DRUG

Pegasys

180 micrograms sc weekly for 24 weeks

DRUG

Pegasys

90 micrograms sc weekly for 24 weeks

DRUG

RO4588161

1000mg po bid for 24 weeks

DRUG

RO4588161

500mg po bid for 24 weeks

DRUG

RO4588161

1500mg po bid for 24 weeks

Trial Locations (63)

1090

Vienna

2050

Sydney

2145

Sydney

3004

Melbourne

4120

Greenslopes

5000

Adelaide

10021

New York

10126

Torino

10468

The Bronx

11030

Manhasset

13285

Marseille

13353

Berlin

17033

Hershey

20246

Hamburg

21287

Baltimore

22031

Fairfax

23249

Richmond

28222

Madrid

30625

Hanover

33604

Pessac

34209

Bradenton

37211

Nashville

40138

Bologna

41014

Seville

46014

Valencia

50937

Cologne

54511

Vandœuvre-lès-Nancy

55446

Plymouth

60590

Frankfurt am Main

60637

Chicago

75014

Paris

75203

Dallas

75651

Paris

78215

San Antonio

79106

Freiburg im Breisgau

80045

Aurora

80110

Englewood

80131

Napoli

84121

Salt Lake City

85054

Phoenix

90822

Long Beach

92118

Clichy

92154

San Diego

94010

Créteil

94115

San Francisco

95817

Sacramento

97239

Portland

92037-1030

La Jolla

92103-8465

San Diego

32610-0214

Gainesville

33136-1051

Miami

27599-7584

Chapel Hill

45267-0595

Cincinnati

02905

Providence

78234-3879

Fort Sam Houston

T2N 4N1

Calgary

V5Z 1H2

Vancouver

V5Z 1M9

Vancouver

K1H 8L6

Ottawa

M5G 1L7

Toronto

00909

Santurce

08915

Badalona

08003

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY